Dynavax Technologies, developers of the first new hepatitis B vaccine in 25 years, released an infographic to educate the health sector and consumers about the vaccine, which has been approved for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.
In particular, the infographic highlights the impact of the opioid epidemic on increases in new cases of hepatitis B, explores challenges in increasing hepatitis B vaccination coverage, and reinforces the role of the vaccine in minimizing and preventing a continued uptick in hepatitis B cases.
View the infographic to learn more.